Filings set for Takeda's ixazomib on Phase III data
This article was originally published in Scrip
Executive Summary
Takeda is set to file for approval worldwide of its leading oral proteasome inhibitor ixazomib in multiple myeloma on the basis of encouraging interim data from the Phase III TOURMALINE-MM1 study.